Susquehanna International Group
AVTX icon

Susquehanna International Group’s Avalo Therapeutics AVTX Stock Holding History

Susquehanna International Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-210,994
Closed -$3.3M – 13146
2025
Q4 		$3.83M Buy
210,994
+163,596
+345% +$2.76M ﹤0.01% 4471
2025
Q3 		$602K Buy
+47,398
New +$408K ﹤0.01% 8541
2023
Q4 		– Sell
-95
Closed -$2.74K – 12319
2023
Q3 		$2.74K Buy
+95
New +$4.24K ﹤0.01% 11825
2023
Q1 		– Sell
-78
Closed -$95K – 12541
2022
Q4 		$95K Buy
+78
New +$102K ﹤0.01% 11000
2022
Q2 		– Sell
-5
Closed -$11K – 12845
2022
Q1 		$11K Sell
5
-4
-44% -$10K ﹤0.01% 12738
2021
Q4 		$45K Buy
9
+2
+29% +$12K ﹤0.01% 12601
2021
Q3 		$46K Sell
7
-37
-84% -$300K ﹤0.01% 12372
2021
Q2 		$412K Buy
44
+16
+57% +$134K ﹤0.01% 10057
2021
Q1 		$246K Buy
28
+19
+211% +$180K ﹤0.01% 11013
2020
Q4 		$68K Buy
9
+3
+50% +$20.8K ﹤0.01% 10660
2020
Q3 		$42K Buy
6
+1
+20% +$7.52K ﹤0.01% 10245
2020
Q2 		$39K Hold
5
– – ﹤0.01% 9809
2020
Q1 		$36K Buy
+5
New +$52.9K ﹤0.01% 9780
2019
Q4 		– Sell
-4
Closed -$35K – 9687
2019
Q3 		$35K Buy
+4
New +$44.6K ﹤0.01% 9862
2019
Q2 		– Sell
-20
Closed -$329K – 10192
2019
Q1 		$329K Buy
+20
New +$299K ﹤0.01% 7057

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Susquehanna International Group's AVTX Position: Q1 2026 in Review

Susquehanna International Group sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 210,994 shares — an estimated $3.3M sold.

Susquehanna International Group first reported a position in AVTX in Q1 2019 and held it in 15 quarters. The position peaked at $3.83M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Susquehanna International Group reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 210,994 Avalo Therapeutics shares in Q1 2026, an estimated $3.3M.
  • Susquehanna International Group first reported a position in Avalo Therapeutics in Q1 2019 and held it in 15 quarters.
  • Susquehanna International Group's Avalo Therapeutics position peaked at $3.83M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.